CLINUVEL PHARMACE
CLINUVEL PHARMACE operates in Diversified Metals & Mining.
CLINUVEL PHARMACE (UR9) - Net Assets
Latest net assets as of June 2024: €203.01 Million EUR
Based on the latest financial reports, CLINUVEL PHARMACE (UR9) has net assets worth €203.01 Million EUR as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€231.12 Million) and total liabilities (€28.11 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €203.01 Million |
| % of Total Assets | 87.84% |
| Annual Growth Rate | 35.53% |
| 5-Year Change | 175.57% |
| 10-Year Change | N/A |
| Growth Volatility | 10.01 |
CLINUVEL PHARMACE - Net Assets Trend (2016–2024)
This chart illustrates how CLINUVEL PHARMACE's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CLINUVEL PHARMACE (2016–2024)
The table below shows the annual net assets of CLINUVEL PHARMACE from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-06-30 | €203.01 Million | +23.31% |
| 2023-06-30 | €164.63 Million | +31.12% |
| 2022-06-30 | €125.56 Million | +27.16% |
| 2021-06-30 | €98.74 Million | +34.03% |
| 2020-06-30 | €73.67 Million | +28.84% |
| 2019-06-30 | €57.18 Million | +45.07% |
| 2018-06-30 | €39.42 Million | +54.91% |
| 2017-06-30 | €25.44 Million | +42.67% |
| 2016-06-30 | €17.83 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CLINUVEL PHARMACE's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 16302686600.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (June 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €29.96 Million | 14.76% |
| Other Components | €173.05 Million | 85.24% |
| Total Equity | €203.01 Million | 100.00% |
CLINUVEL PHARMACE Competitors by Market Cap
The table below lists competitors of CLINUVEL PHARMACE ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Artec Consulting Corp
PINK:ACTL
|
$69.28K |
|
Globavend Holdings Limited Ordinary Shares
NASDAQ:GVH
|
$69.31K |
|
Runway Growth Finance Corp
NASDAQ:RWAY
|
$69.37K |
|
WEGE3F
SA:WEGE3F
|
$69.40K |
|
CANACCORD GENUITY
BE:C6U
|
$69.16K |
|
LIFE + BANC SPLIT
F:74F
|
$69.14K |
|
PROXIMUS (BX7.SG)
STU:BX7
|
$69.11K |
|
STOKVIS NORD AFRIQUE
BC:STOKVIS-NORD-AFRIQUE
|
$69.10K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CLINUVEL PHARMACE's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 164,631,143 to 203,011,366, a change of 38,380,223 (23.3%).
- Net income of 35,636,359 contributed positively to equity growth.
- Dividend payments of 2,470,227 reduced retained earnings.
- Share repurchases of 4,909,246 reduced equity.
- New share issuances of 4,155,010 increased equity.
- Other factors increased equity by 5,968,327.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €35.64 Million | +17.55% |
| Dividends Paid | €2.47 Million | -1.22% |
| Share Repurchases | €4.91 Million | -2.42% |
| Share Issuances | €4.16 Million | +2.05% |
| Other Changes | €5.97 Million | +2.94% |
| Total Change | €- | 23.31% |
Book Value vs Market Value Analysis
This analysis compares CLINUVEL PHARMACE's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.75x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 13.35x to 1.75x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-06-30 | €0.53 | €7.10 | x |
| 2018-06-30 | €0.82 | €7.10 | x |
| 2019-06-30 | €1.17 | €7.10 | x |
| 2020-06-30 | €1.49 | €7.10 | x |
| 2021-06-30 | €2.00 | €7.10 | x |
| 2022-06-30 | €2.54 | €7.10 | x |
| 2023-06-30 | €3.33 | €7.10 | x |
| 2024-06-30 | €4.05 | €7.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CLINUVEL PHARMACE utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.55%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 40.41%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.14x
- Recent ROE (17.55%) is below the historical average (19.58%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -17.72% | -50.77% | 0.31x | 1.13x | €-4.93 Million |
| 2017 | 28.29% | 42.95% | 0.58x | 1.13x | €4.64 Million |
| 2018 | 33.55% | 51.89% | 0.59x | 1.09x | €9.28 Million |
| 2019 | 31.71% | 58.41% | 0.50x | 1.09x | €12.42 Million |
| 2020 | 22.60% | 51.12% | 0.40x | 1.11x | €9.28 Million |
| 2021 | 25.04% | 51.54% | 0.44x | 1.10x | €14.85 Million |
| 2022 | 16.63% | 31.77% | 0.46x | 1.15x | €8.32 Million |
| 2023 | 18.59% | 39.08% | 0.40x | 1.18x | €14.14 Million |
| 2024 | 17.55% | 40.41% | 0.38x | 1.14x | €15.34 Million |
Industry Comparison
This section compares CLINUVEL PHARMACE's net assets metrics with peer companies in the Other industry.
Industry Context
- Industry: Other
- Average net assets among peers: $114,212,818,724
- Average return on equity (ROE) among peers: -9.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CLINUVEL PHARMACE (UR9) | €203.01 Million | -17.72% | 0.14x | $69.22K |
| HORIBA (01H) | $204.49 Billion | 10.42% | 0.82x | $989.01K |
| Tokyu Corporation (01T) | $779.37 Billion | 3.34% | 2.35x | $99.73K |
| GUANGZHOU AUTO -H- (02G) | $122.28 Billion | 6.59% | 0.55x | $4.05K |
| MOSAIC (02M) | $10.60 Billion | 4.43% | 0.90x | $280.83K |
| MOSAIC (02M.SG) (02M) | $9.56 Billion | 10.46% | 0.82x | $247.21K |
| CHINA JO-JO DRGSTRS (04CN.SG) (04CN) | $16.67 Million | -126.83% | 4.46x | $1.55 Million |
| KRAKATAU STEEL -B- (07K) | $552.59 Million | 3.52% | 4.72x | $166.99 |
| CN MODERN DAIRY (07M) | $7.12 Billion | -10.42% | 1.50x | $1.68K |
| TOURMALINE OIL (08T) | $7.22 Billion | 4.81% | 0.41x | $381.02K |
| ASIA CASSAVA RESOUR (0ACS) | $913.15 Million | 2.86% | 1.55x | $325.03 |